Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 11/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21736622 | 0.90 | KLKB1 (0.48) | KLKB1 | |
| SCHEMBL21736873 | 0.89 | KLKB1 (0.36) | KLKB1POLBNR1H2SMN1; SMN2KDM4E | |
| SCHEMBL21736620 | 0.84 | KLKB1 (0.47) | KLKB1 | |
| SCHEMBL21736879 | 0.83 | KLKB1 (0.46) | KLKB1NR1H2 | |
| SCHEMBL21736621 | 0.83 | KLKB1 (0.45) | KLKB1 | |
| SCHEMBL21736629 | 0.82 | KLKB1 (0.55) | KLKB1 | |
| SCHEMBL21736734 | 0.77 | KLKB1 (0.41) | KLKB1POLBMAPTKDM4EALDH1A1 | |
| SCHEMBL21736642 | 0.76 | KLKB1 (0.44) | KLKB1NR1H2 | |
| SCHEMBL22166231 | 0.75 | KLKB1 (0.44) | KLKB1NR1H2 | |
| SCHEMBL24105413 | 0.73 | KLKB1 (0.49) | KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210387963-A1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-12-16 | — | — | US | disclosed |
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| WO-2020035540-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-02-20 | — | — | WO | disclosed |
| US-20200054617-A1 | Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387963-A1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, SERPINB1 | KLKB1 1/4885POLB 4132/4885MAPT 2618/4885 |
| US-20200054617-A1 | Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885POLB 3970/4885MAPT 3454/4885 |
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885POLB 3970/4885MAPT 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.